U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H25F3N4O
Molecular Weight 370.4125
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ORG-13011

SMILES

FC(F)(F)C1=CC(=NC=C1)N2CCN(CCCCN3CCCC3=O)CC2

InChI

InChIKey=YKJJCYZZWWSBEW-UHFFFAOYSA-N
InChI=1S/C18H25F3N4O/c19-18(20,21)15-5-6-22-16(14-15)24-12-10-23(11-13-24)7-1-2-8-25-9-3-4-17(25)26/h5-6,14H,1-4,7-13H2

HIDE SMILES / InChI

Molecular Formula C18H25F3N4O
Molecular Weight 370.4125
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

PubMed

PubMed

TitleDatePubMed
Strychnine seizure potentiation by azaspirodecanedione anxiolytics in rats.
1988 Oct 18
Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction.
1989
Prenatal exposure to cocaine: effects on aggression in Sprague-Dawley rats.
1994 May
5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.
2000 Dec
Involvement of 5-hydroxytryptamine(1A) receptors in nicotine-induced tail tremor in rats.
2000 Nov 10
Gepirone. Organon.
2001 Aug
Effects of serotonergic compounds on aqueous humor dynamics in monkeys.
2001 Aug
The clinical pharmacology of depressive states.
2002 Mar
Rigid analogues of buspirone and gepirone, 5-HT1A receptors partial agonists.
2002 Nov
5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain.
2002 Oct 4
Influence of housing conditions on the effects of serotonergic drugs on feeding behavior in non-deprived rats.
2003
Is there a role for 5-HT1A agonists in the treatment of depression?
2003 Feb 1
A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone.
2003 Jun
Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
2003 Mar
Human cytochromes mediating gepirone biotransformation at low substrate concentrations.
2003 Mar
Differential effects of the 5-HT1A agonist gepirone on food intake in rats may depend on their motivation to eat.
2003 Nov
Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers.
2003 Sep
The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands.
2004 Apr 5
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
2004 Aug
[Review of antidepressants from the TCAs to the third generation drugs].
2004 Dec
Metabolism of the newest antidepressants: comparisons with related predecessors.
2004 Feb
Cellular consequences of stress and depression.
2004 Jun
Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines.
2004 Mar
Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
2004 May-Jun
Relapse prevention with gepirone ER in outpatients with major depression.
2005 Feb
Novel, flexible, and conformationally defined analogs of gepirone: synthesis and 5-HT1A, 5-HT2A, and D2 receptor activity.
2005 Feb 15
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients.
2005 Jun
The 5-HT1A receptor and the stimulus effects of LSD in the rat.
2005 Oct
Early response and 8-week treatment outcome in GAD.
2006
Acute and constitutive increases in central serotonin levels reduce social play behaviour in peri-adolescent rats.
2007 Dec
Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.
2008 Apr
Differential response to gepirone but not to chlordiazepoxide in malnourished rats subjected to learned helplessness.
2008 Jan
Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models.
2008 Sep
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.
2009
Emotional reactivity and cognitive performance in aversively motivated tasks: a comparison between four rat strains.
2009 Dec 15
Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder.
2010 Apr 23
Patents
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:17:34 GMT 2023
Edited
by admin
on Sat Dec 16 10:17:34 GMT 2023
Record UNII
TG6TYE3R9N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ORG-13011
Common Name English
2-PYRROLIDINONE, 1-(4-(4-(4-(TRIFLUOROMETHYL)-2-PYRIDINYL)-1-PIPERAZINYL)BUTYL)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID001037020
Created by admin on Sat Dec 16 10:17:34 GMT 2023 , Edited by admin on Sat Dec 16 10:17:34 GMT 2023
PRIMARY
CAS
142494-12-0
Created by admin on Sat Dec 16 10:17:34 GMT 2023 , Edited by admin on Sat Dec 16 10:17:34 GMT 2023
PRIMARY
PUBCHEM
9907401
Created by admin on Sat Dec 16 10:17:34 GMT 2023 , Edited by admin on Sat Dec 16 10:17:34 GMT 2023
PRIMARY
FDA UNII
TG6TYE3R9N
Created by admin on Sat Dec 16 10:17:34 GMT 2023 , Edited by admin on Sat Dec 16 10:17:34 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY